This is an aggregated industry headline. Read the full story at PharmaVoice →
HHS, responding to China's rise, moves to fast-track early drug research
A series of newly planned reforms are designed to entice companies to start early trials in the U.S. rather than overseas.
By PharmaVoice
· Jun 24, 2026
· via PharmaVoice
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlinePharmaVoice
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
As Amgen prepares to defend Tavneos' market approval in the U.S., the company has received a bad omen overseas…
The WeekFierceBiotech ↗
AstraZeneca has shared the data behind previously disclosed phase 3 rare disease wins, fleshing out the case f…
The WeekBriefing
STAT News flagged two developments: a congressional bill to revamp the 340B drug discount program and talk of …